BioInvent International: BioInvent Announces Additional Efficacy Data from Intravenous Part of Phase 1/2 Trial with BI-1206 in Solid Tumors

One additional patient has developed a partial response (PR) and one patient has remained on stable disease for over 80 weeksThese long-lasting responses in hard-to-treat metastatic diseases, in patients

Related Keywords

Zeiten ,Mecklenburg Vorpommern ,Germany ,United States ,Stefan Klotter ,Cecilia Hofvander ,Martin Welschof ,Bioinvent Internationalview ,Bioinvent International Ab Nasdaq Stockholm ,Bioinvent International ,Bioinvent International Ab ,Twitter ,Merck Co Inc ,Merck Sharp Dohme ,Merck Sharp ,Nasdaq Stockholm ,Senior Director Investor ,Stabile Ertr ,Chart Profi Stefan Klotter ,Blue Chips ,Bioinvent ,Nternational ,Nnounces ,Dditional ,Efficacy ,Data ,Rom ,Intravenous ,Art ,Hase ,Trial ,206 ,Olid ,Rumors ,